JAKARTA - Coordinating Minister for Maritime Affairs and Investment Luhut Binsar Pandjaitan confirmed that the US pharmaceutical company Pfizer would invest in a number of sectors, particularly those related to the handling of the COVID-19 pandemic.
Furthermore, Luhut admitted that he had conducted an assessment with Pfizer and Merck, which are currently producing COVID-19.
"This morning I spoke with Pfizer. Four days ago with Merck. It turns out they want to go to Indonesia. So far they have said, 'Yes, we are difficult'. That's why I and Pak Budi (Minister of Health) told Pfizer to just put it here We agree that several fields of Pfizer technology will enter Indonesia," he said during a virtual discussion, quoted Thursday, November 18.
Luhut hopes that starting next year there will be a number of industries developed in the country. Especially with regard to the handling of the COVID-19 pandemic.
"We hope that starting next year there will be more industries from Pfizer in Indonesia," he said.
For your information, Pfizer itself was present in Indonesia since 1969, until then inaugurated its first factory facility in 1971. Currently, Pfizer Indonesia operates a manufacturing facility that produces various types of medical drugs to meet domestic needs and neighboring countries in Southeast Asia.
Previously, the Indonesian government met with pharmaceutical manufacturers Merck and Pfizer in the United States. The meeting was represented by Coordinating Minister for Maritime Affairs and Investment Luhut binsar Panjaitan and Minister of Health Budi Gunadi Sadikin. There, they persuaded the two pharmaceutical manufacturers to want to build factories in Indonesia.
This step is an effort by the government so that Indonesia is no longer an importing country because the raw materials for medicines are always imported from outside.
The reason is, because Indonesia has been depending on raw materials for medicines, this has actually caused problems such as the difficulty of finding medicines that contain paracetamol. This is because India as a supplying country has closed access to the effects of the COVID-19 pandemic. In fact, the drug is very much needed.
As a result of this bitter experience, Luhut finally asked the importers to end it and encourage investment to develop the country.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
